Wisconsin State Journal: Exact Sciences reports revenue jumped nearly 80% for the first quarter

Wisconsin State Journal: Exact Sciences reports revenue jumped nearly 80% for the first quarter

More than 100,000 people a month, on average, are being screened for colorectal cancer using Cologuard, the Madison company that makes the diagnostic test disclosed Tuesday.

“Cologuard is changing how Americans get screened for colorectal cancer,” said Exact Sciences Corp. CEO and chairman Kevin Conroy.

Exact Sciences said it processed 334,000 of the DNA-based stool tests during the first quarter of 2019, up 79% from the 186,000 tests that came through in the first three months of 2018.

Revenue was $162 million, up from $90.3 million for last year’s first quarter.

Read the full Wisconsin State Journal article here.